CDMO Committed Capacity Assessment: Preview Report
A free preview of how ProGen's CDMO Committed Capacity Assessment is built. It places contract manufacturing capacity in biologics, sterile fill-finish, ADC bioconjugation, highly potent small molecules, peptides, oral solids, cell and gene therapy and radiopharmaceuticals on four tiers, Announced, Commissioned, Qualified and Committed, site by site, and attaches the ownership, compliance, leadership and trade-policy events that change what can be scheduled. Results are reserved for buyers.
Built to order · Research cut-off: 18 November 2026

What this report answers
- How much announced CDMO capacity is actually schedulable, and how is that tested site by site?
- What evidence moves a site from announced to commissioned, qualified and committed?
- How is committed capacity read when operators rarely publish utilization?
- Which events, from a change of owner to an FDA warning letter, change what a site can schedule?
- What does a buyer of the full assessment receive?
343 site-assets
Across 156 company groups in 30 countries, with each record's tier or closure status.
510 public source documents
Behind about 850 evidence records, current to 18 November 2026.
What the analysis establishes
Four tiers of capacity
Announced, Commissioned, Qualified and Committed, each with a written evidence test. Schedulable capacity is qualified capacity that is not yet committed. A record moves up a tier only when public evidence meets that tier's test, and where evidence is missing the record says so.
Ten modalities, never added together
Biologics drug substance (mammalian and microbial), sterile fill-finish, ADC bioconjugation, highly potent small molecules, peptides, oral solid dose, viral vector, cell therapy and radiopharmaceuticals. Capacity is kept in the unit each operator publishes, from bioreactor liters to filling lines and dose output.
The overlays
Change of owner, closures and impairments, FDA compliance actions including warning letters and complete response letters that cite a site, leadership moves and the BIOSECURE provisions, each attached to the site-asset it affects with its date and source.
What counts as committed
Reservation and supply agreements, single-customer dedication, sold-out statements, contracted backlog and captive use, each labeled by strength. The preview shows the structure of one site record with its values withheld.
Built to your decision
Each assessment is scoped to the decision in front of you, whether a provider, a target, a modality or a supply decision, and quoted on request.
About this intelligence
About 850 evidence records from 510 public source documents, more than 70 percent checked against their source. Sources include company disclosures and filings, regulator records, legislative records and trade press. Other sources are proprietary ProGen intelligence sources. Interpretation is labeled "ProGen reading". Evidence is current to 18 November 2026.
Investors diligencing a CDMO or a CDMO-dependent asset. Sponsors securing fill-finish, biologics, ADC, peptide or radiopharma capacity. Corporate development teams weighing build, buy or partner. CDMO leadership teams reading competitors and customers.
Contents
- Why a committed capacity assessment
- The questions it answers
- How the assessment is built
- Four tiers of capacity
- Ten modalities
- Where the sites are
- What moves a site's capacity
- Commitment: what counts as booked
- One site record
- The evidence base
- What a buyer receives
Modalities covered
Biologics drug substance, mammalian, Biologics drug substance, microbial, Sterile fill-finish, ADC bioconjugation, Highly potent small molecules, Peptides, Oral solid dose, Viral vector, Cell therapy, Radiopharmaceuticals
The full 8-page briefing is free. Tell us where to send it and it downloads immediately.
CDMO Committed Capacity Assessment
Built to your question and quoted individually: how much CDMO capacity is genuinely schedulable, and who is crowding whom out.
See the analysis →